Nimorazole

Summary

Nimorazole (CHEMBL435966) is a phase-3 clinical-stage small molecule (ATC P01AB06); indicated across 3 conditions including amebiasis and head and neck squamous cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: P01AB06
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 226.23 Da · C9H14N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL435966
Name	Nimorazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	23009
ATC	P01AB06
Molecular formula	C9H14N4O3
Molecular weight	226.23
InChIKey	MDJFHRLTPRPZLY-UHFFFAOYSA-N

SMILES: C1COCCN1CCN2C=NC=C2[N+](=O)[O-]

IUPAC name: 4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine

Also known as: K-1900, Naxogin, Naxogin 500, Nimorazol, Nimorazole, NSC-107524, SID92764328, Nitrimidazine, nimorazole, SID170466578, NIMORAZOLE

Patent coverage: 1,607 distinct patent families (6,782 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
amebiasis	4	MONDO:0005644	EFO:0007144
head and neck squamous cell carcinoma	3	MONDO:0010150	EFO:0000181
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01507467	PHASE3	TERMINATED	IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck
NCT01880359	PHASE3	UNKNOWN	AF CRT +/- Nimorazole in HNSCC
NCT01950689	PHASE3	COMPLETED	NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)
NCT02661152	PHASE3	UNKNOWN	DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).